How many clinical trials are there for PIK3CA-related Overgrowth Spectrum (PROS)?

PlainTrial tracks 4 US clinical trials for PIK3CA-related Overgrowth Spectrum (PROS), of which 2 are currently recruiting.

Which interventions appear most often on PIK3CA-related Overgrowth Spectrum (PROS) trial records?

Alpelisib is the most-linked intervention name on PIK3CA-related Overgrowth Spectrum (PROS) records (3 trial links), followed by Placebo. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for PIK3CA-related Overgrowth Spectrum (PROS)?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

PIK3CA-related Overgrowth Spectrum (PROS): early-phase trial registry

Compiled by PlainTrial · August 8, 2026

2 of 4 indexed PIK3CA-related Overgrowth Spectrum (PROS) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count

PIK3CA-related Overgrowth Spectrum (PROS): 4 US clinical trials tracked, 2 recruiting.

PIK3CA-related Overgrowth Spectrum (PROS) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 3 of these trials.

Enrollment posture brief

Registry condition pik3ca-related-overgrowth-spectrum-pros

Volume-matched condition peers

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Open-enrollment share among volume-matched conditions near PIK3CA-related Overgrowth Spectrum (PROS)

PIK3CA-related Overgrowth Spectrum (PROS) lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for PIK3CA-related Overgrowth Spectrum (PROS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

PIK3CA-related Overgrowth Spectrum (PROS) is recruiting above its size-band peers.

2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Open and recent trials

4 total, page 1 of 1

RECRUITING Phase 2 277 participants

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Relay Therapeutics

NCT06789913

RECRUITING Phase 2 104 participants

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Novartis Pharmaceuticals

NCT06997588

ACTIVE NOT RECRUITING Phase 2 206 participants

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Novartis Pharmaceuticals

NCT04589650

ACTIVE NOT RECRUITING Phase 2 41 participants

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

Novartis Pharmaceuticals

NCT04980833

Phase Distribution

Phase	Trial count
Phase 2	4

Top Sponsors

Novartis Pharmaceuticals 3 trials

Relay Therapeutics 1 trials

Named interventions

Most-linked intervention names on PIK3CA-related Overgrowth Spectrum (PROS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Alpelisib Drug

3 trials

Placebo Drug

2 trials

RLY-2608 Drug

1 trials

US sites by state

Facility locations filed on PIK3CA-related Overgrowth Spectrum (PROS) trials. A trial with sites in several states counts in each.

Missouri 3 trials

Texas 2 trials

Ohio 2 trials

North Carolina 2 trials

Massachusetts 2 trials

Colorado 2 trials

California 2 trials

Wisconsin 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Read our methodology - how this data is sourced, computed, and verified.

What to do with this PIK3CA-related Overgrowth Spectrum (PROS) page

4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

2 PIK3CA-related Overgrowth Spectrum (PROS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
Novartis Pharmaceuticals sponsors the most PIK3CA-related Overgrowth Spectrum (PROS) trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This PIK3CA-related Overgrowth Spectrum (PROS) condition card totals 4 registered trials; most-linked intervention Alpelisib; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.